journal
Frontage Laboratories has validated an exome sequencing assay that demonstrates high concordance between Gradalis Inc.’s Vigil® product and the originating autologous tumor—preserving clonal tumor mutational burden, neoantigen load, and intratumor heterogeneity. With correlation scores above 0.87, our platform confirms the fidelity of personalized cancer vaccines. This service empowers immunotherapy developers with reliable tumor profiling to support product validation, patient selection, and next-generation cancer vaccine strategies.
Register to gain access to gated resources.
"*" indicates required fields
Frontage Laboratories websites use cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details about cookies, and their use, please see our privacy policy.
Websites store cookies to enhance functionality and personalise your experience. You can manage your preferences, but blocking some cookies may impact site performance and services.
Essential cookies enable basic functions and are necessary for the proper function of the website.